Projects per year
Abstract
Resistance to currently available antifungal drugs has quietly been on the rise but overshadowed by the alarming spread of antibacterial resistance. There is a striking lack of attention to the threat of drug-resistant fungal infections, with only a handful of new drugs currently in development. Given that metal complexes have proven to be useful new chemotypes in the fight against diseases such as cancer, malaria, and bacterial infections, it is reasonable to explore their possible utility in treating fungal infections. Herein we report a series of cobalt(III) Schiff base complexes with broad-spectrum antifungal activity. Some of these complexes show minimum inhibitory concentrations (MIC) in the low micro- to nanomolar range against a series of Candida and Cryptococcus yeasts. Additionally, we demonstrate that these compounds show no cytotoxicity against both bacterial and human cells. Finally, we report the first in vivo toxicity data on these compounds in Galleria mellonella, showing that doses as high as 266 mg kg−1 are tolerated without adverse effects, paving the way for further in vivo studies of these complexes.
Original language | English |
---|---|
Pages (from-to) | 2021-2029 |
Number of pages | 9 |
Journal | Chemistry - A European Journal |
Volume | 27 |
Issue number | 6 |
Early online date | 24 Nov 2020 |
DOIs | |
Publication status | Published - 26 Jan 2021 |
Bibliographical note
Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.Keywords
- antifungal agents
- cobalt
- metallodrugs
- Schiff base complexes
Fingerprint
Dive into the research topics of 'Nontoxic cobalt(III) Schiff base complexes with broad‐spectrum antifungal activity'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Stronger Together: Understanding Antibiotic Synergy on a Molecular Level
3/12/18 → 3/12/21
Project: Research